Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Rabies - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rabies - Pipeline Review, H1 2017, provides an overview of the Rabies (Infectious Disease) pipeline landscape. Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, swallowing difficult, excitability, fever and convulsions. The predisposing factors include exposure to wildlife and exposure to other pets that may not be vaccinated. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rabies - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rabies (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Rabies (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rabies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 2, 10, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively. Rabies (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Rabies (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Rabies (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Rabies (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Rabies (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Rabies (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Rabies (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Rabies (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Rabies - Overview Rabies - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Rabies - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Rabies - Companies Involved in Therapeutics Development Beijing Minhai Biotechnology Co Ltd Celltrion Inc Curevac AG Humabs BioMed SA Indian Immunologicals Ltd Kamada Ltd Molecular Targeting Technologies Inc NanoViricides Inc Novavax Inc PaxVax Inc Sanofi Pasteur SA Synermore Biologics Co Ltd Trellis Bioscience Inc VBI Vaccines Inc Zydus Cadila Healthcare Ltd Rabies - Drug Profiles (Ebola [Zaire] + rabies) (bivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress BNSP-333S1 - Drug Profile Product Description Mechanism Of Action R&D Progress CTP-19 - Drug Profile Product Description Mechanism Of Action R&D Progress CV-8102 - Drug Profile Product Description Mechanism Of Action R&D Progress IMT-504 - Drug Profile Product Description Mechanism Of Action R&D Progress MAb-3 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies for Rabies - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies to Inhibit Glycoprotein for Rabies - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies to Target Glycoprotein for Rabies - Drug Profile Product Description Mechanism Of Action R&D Progress nadorameran - Drug Profile Product Description Mechanism Of Action R&D Progress RabiCide-I - Drug Profile Product Description Mechanism Of Action R&D Progress rabies [strain Wistar PM/WI 38-1503-3M] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress rabies immune globulin (human) - Drug Profile Product Description Mechanism Of Action R&D Progress rabies vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress rabies vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress rabies vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress rabies vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress rabies vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress rabies vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress rabies vaccine 1 - Drug Profile Product Description Mechanism Of Action R&D Progress Rabimabs - Drug Profile Product Description Mechanism Of Action R&D Progress RabiVir - Drug Profile Product Description Mechanism Of Action R&D Progress RVC-20 - Drug Profile Product Description Mechanism Of Action R&D Progress RVC-58 - Drug Profile Product Description Mechanism Of Action R&D Progress SO-57 - Drug Profile Product Description Mechanism Of Action R&D Progress SOJB - Drug Profile Product Description Mechanism Of Action R&D Progress SYN-023 - Drug Profile Product Description Mechanism Of Action R&D Progress YSON-001 - Drug Profile Product Description Mechanism Of Action R&D Progress Rabies - Dormant Projects Rabies - Product Development Milestones Featured News & Press Releases Jan 11, 2017: CureVac Provides Clinical Update on CV7201 at 35th Annual J.P. Morgan Healthcare Conference Jan 04, 2017: US FDA Grants Orphan Drug Designation to Yisheng Biopharma's PIKA Rabies Vaccine Nov 07, 2016: Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment Sep 01, 2016: Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant Dec 23, 2015: Kamada's Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment Mar 23, 2015: Yisheng Biopharma develops new therapeutic vaccine for rabies Mar 04, 2014: Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies Aug 28, 2009: Rabies Vaccine Supply Update: IMOVAX Rabies Vaccine Availability Jul 15, 2008: Kamada Gains Approval of KamRAB in Israel Oct 23, 2007: Kamada Awarded Another Contract To Deliver Its KamRAB Anti-rabies Vaccination To Latin America May 01, 2007: Kamada Obtains FDA Approval to Commence Phase II and III Clinical Trials For Its KamRAB Anti-rabies Passive Immunization Product Sep 18, 2003: Molecular Targeting Technologies, Inc. Forms Partnership With North China Pharmaceutical Company Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Rabies, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Rabies - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017 Rabies - Pipeline by Celltrion Inc, H1 2017 Rabies - Pipeline by Curevac AG, H1 2017 Rabies - Pipeline by Humabs BioMed SA, H1 2017 Rabies - Pipeline by Indian Immunologicals Ltd, H1 2017 Rabies - Pipeline by Kamada Ltd, H1 2017 Rabies - Pipeline by Molecular Targeting Technologies Inc, H1 2017 Rabies - Pipeline by NanoViricides Inc, H1 2017 Rabies - Pipeline by Novavax Inc, H1 2017 Rabies - Pipeline by PaxVax Inc, H1 2017 Rabies - Pipeline by Sanofi Pasteur SA, H1 2017 Rabies - Pipeline by Synermore Biologics Co Ltd, H1 2017 Rabies - Pipeline by Trellis Bioscience Inc, H1 2017 Rabies - Pipeline by VBI Vaccines Inc, H1 2017 Rabies - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017 Rabies - Dormant Projects, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
